Home›Trial›NCT03319940
🔬NCT03319940Phase 1ACTIVE NOT RECRUITING

Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)

Study Summary

A study to assess the safety, tolerability, and PK of tarlatamab in participants with SCLC

Conditions
Small Cell Lung Carcinoma
Interventions / Drugs
TarlatamabPembrolizumabCRS Mitigation Strategies
View on ClinicalTrials.gov ↗
Sponsor
AMGN
Amgen Inc
Biologics
F33/100
Study Details
Enrollment269 participants
Primary Completion—
Lead SponsorAmgen
Data Retrieved2026-04-13 18:29:34.157872+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.